IBJNews

Indiana's life sciences industry sees trouble ahead

Back to TopCommentsE-mailPrintBookmark and Share

Long sold as one of the state's brightest economic hopes, Indiana's life sciences industry has weathered the recession relatively well.

Total employment is up nearly 7 percent and major investment announcements are trickling in.

Signs of trouble, however, loom. Indianapolis-based Eli Lilly and Co., arguably Indiana's life sciences engine, continues to shed jobs. The state government's direct investments into the industry's smallest companies are down.

And, perhaps most ominously, tighter capital markets threaten to starve the risky process of medical innovation.

"That is the legacy of this recession. Not one or two missed companies, but a changed capital market," said David Johnson, president and CEO of BioCrossroads, a statewide life sciences organization.

"The challenges of getting capital are going to be permanently harder."

At the moment, however, the industry is still producing new jobs.

Statewide, life sciences employment is up 6.5 percent since the recession hit, according to data from the U.S. Bureau of Labor Statistics. The bureau tracks the medical supplies manufacturing as well as medical and diagnostic laboratories sectors.

More Hoosiers were working in those sectors in August 2010, 26,200 people, than at any time in the last decade, the data shows.

More jobs could be coming, too.

This summer, several life science firms across the state announced significant investment plans.

In Warsaw, orthopedic device manufacturer Biomet Inc., will invest $26 million and create 280 jobs, officials have said.

In Indianapolis, Beckman Coulter plans to spend $18.2 million and create 95 jobs. In Greenwood, Advantis Medical intends to add 100 positions with a $6 million expansion.

In early 2010, a $85 million manufacturing facility opened by Cook Pharmica in Bloomington created more than 100 jobs.

While many of the mid-size firms are expanding, Indiana's life sciences giant is pulling back.

Lilly is in the midst of the largest restructuring in its 134-year history, and aims to cut 5,500 jobs worldwide and $1 billion in annual costs by December.

The hope among business leaders is that former Lilly employees in Indiana stay here, and join other life sciences companies.

"The goal is 'brain neutral,' not 'brain drain,'" Bart Peterson, a senior vice president with Lilly and a former mayor of Indianapolis, said this summer.

An important part of that effort is funding startups, experts said. The state's 21st Century Fund tries to do exactly that, offering early-stage investments to promising young companies.

However, the fund's investments in the life sciences have steadily fallen during the recession — from $14.6 million in 2007-2008 to just $6.6 million in 2009-2010 — even as normal venture capital also disappears.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. John, unfortunately CTRWD wants to put the tank(s) right next to a nature preserve and at the southern entrance to Carmel off of Keystone. Not exactly the kind of message you want to send to residents and visitors (come see our tanks as you enter our city and we build stuff in nature preserves...

  2. 85 feet for an ambitious project? I could shoot ej*culate farther than that.

  3. I tried, can't take it anymore. Untill Katz is replaced I can't listen anymore.

  4. Perhaps, but they've had a very active program to reduce rainwater/sump pump inflows for a number of years. But you are correct that controlling these peak flows will require spending more money - surge tanks, lines or removing storm water inflow at the source.

  5. All sewage goes to the Carmel treatment plant on the White River at 96th St. Rainfall should not affect sewage flows, but somehow it does - and the increased rate is more than the plant can handle a few times each year. One big source is typically homeowners who have their sump pumps connect into the sanitary sewer line rather than to the storm sewer line or yard. So we (Carmel and Clay Twp) need someway to hold the excess flow for a few days until the plant can process this material. Carmel wants the surge tank located at the treatment plant but than means an expensive underground line has to be installed through residential areas while CTRWD wants the surge tank located further 'upstream' from the treatment plant which costs less. Either solution works from an environmental control perspective. The less expensive solution means some people would likely have an unsightly tank near them. Carmel wants the more expensive solution - surprise!

ADVERTISEMENT